Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapastinel as Adjunctive Therapy in MDD (RAP-MD-03)
NCT02943577Phase 3Completed
- Sponsor
- Allergan
- Start
- Nov 2016
- Primary completion
- Oct 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rapastinel in major depressive disorder (MDD), sponsored by Allergan. Started Nov 2016; status: completed.
02
Drugs
rapastinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02943577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02943577.